Key result
Intravenous ANP significantly increased circumflex coronary artery diameter by up to 2.9% (p<0.05) at high plasma levels, an effect completely suppressed by the ANP receptor antagonist HS-142-1.
Why the study?
Does intravenous ANP affect circumflex coronary artery diameter and coronary blood flow in chronically instrumented dogs?
Does intravenous ANP affect circumflex coronary artery diameter and coronary blood flow in chronically instrumented dogs?
p-value: p=< 0.05
Intravenous ANP significantly increases epicardial coronary artery diameter in vivo, an effect mediated by ANP receptors and associated with increased cGMP, suggesting a compensatory vasodilatory role in conditions like severe heart failure.
No takes yet. Share an insight, caveat, or question.
Supports ANP-mediated coronary vasodilation in vivo; leaves open translation to human HF.
Liu et al. (1996) studied this question. Intravenous atrial natriuretic peptides (ANP) and/or HS-142-1 vs. Control conditions was evaluated on Circumflex coronary artery diameter (CoD) and coronary blood flow (CBF) (p=< 0.05). Intravenous ANP significantly increased circumflex coronary artery diameter by up to 2.9% (p<0.05) at high plasma levels, an effect completely suppressed by the ANP receptor antagonist HS-142-1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: